Q-omics provides the consensus-scored PRKXP1 profile across patient tissues and cancer cell-line models. PRKXP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, PRKXP1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PRKXP1 RNA expression shows 17,826 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, THCA, and THYM as cancer lineages where PRKXP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKXP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKXP1 survival associations across molecular data types. PRKXP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKXP1 RNA expression–survival associations across cancer types. High PRKXP1 expression shows unfavorable associations in KICH and DLBC, but favorable associations in ESCA, SKCM, STAD and UVM. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify ESCA as the clearest survival context for PRKXP1 RNA expression.
This table summarizes PRKXP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRKXP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKXP1 shows lower tumor expression in THCA, KIRP, BRCA and LUAD and higher tumor expression in STAD and CHOL. The THCA box plot shows higher PRKXP1 RNA expression in normal versus tumor tissue (log2 FC = −0.920, t-test p < 0.001).
This table shows molecular features associated with PRKXP1 in patient tissues and cancer cell lines. In patient samples, PRKXP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKXP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
